Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Baird also maintained a Buy rating on the stock with a $300.00 price target. The company has a one-year high of $268.30 and a one-year low of $163.35. Currently, Biogen has an average volume of 1.24M.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

Fashion companies Capri ( CPRI) and Tapestry ( TPR) have mutually decided to abandon their $8.5 billion merger. The companies cited regulatory hurdles, saying in a statement "the required closing ...

If you’ve been waiting to take a punt on a dedicated portable music player for your hi-res music enjoyment, then I have good news. As part of an early Black Friday deal, the two-time What Hi-Fi? Award ...

The adjustment follows Biogen's third-quarter financial report, which presented revenue aligning with forecasts and earnings per share surpassing expectations. The company also increased its earnings ...

The investment firm maintained its Overweight rating on the stock, indicating a positive outlook on the company's trajectory. The price target adjustment follows Biogen's strong performance in the ...